Next Article in Journal
The Relevance of Thiamine Evaluation in a Practical Setting
Next Article in Special Issue
Evaluation of the Ability of Diet-Tracking Mobile Applications to Estimate Energy and Nutrient Intake in Japan
Previous Article in Journal
Effects of Human Milk Oligosaccharides on the Adult Gut Microbiota and Barrier Function
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 12
Issue 9
10.3390/nu12092809
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Protein-Energy Wasting Assessment and Clinical Outcomes in Patients with Acute Kidney Injury: A Systematic Review with Meta-Analysis

by
Ban-Hock Khor
1,
Hui-Ci Tiong
1,
Shing Cheng Tan
2,
Raha Abdul Rahman
3 and
Abdul Halim Abdul Gafor
1,*
1
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
2
UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
3
Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur 56000, Malaysia
*
Author to whom correspondence should be addressed.
Nutrients 2020, 12(9), 2809; https://doi.org/10.3390/nu12092809
Submission received: 13 July 2020 / Revised: 23 August 2020 / Accepted: 10 September 2020 / Published: 13 September 2020
(This article belongs to the Special Issue Nutrition Assessment Methodology: Current Update and Practice)
Browse Figures
Versions Notes

Abstract

:
Nutritional assessment is essential to identify patients with acute kidney injury (AKI) who are protein-energy wasting (PEW) and at risk of poor clinical outcomes. This systematic review aimed to investigate the relationship of nutritional assessments for PEW with clinical outcomes in patients with AKI. A systematic search was performed in PubMed, Scopus, and Cochrane Library databases using search terms related to PEW, nutrition assessment, and AKI to identify prospective cohort studies that involved AKI adult patients with at least one nutritional assessment performed and reported relevant clinical outcomes, such as mortality, length of stay, and renal outcomes associated with the nutritional parameters. Seventeen studies reporting eight nutritional parameters for PEW assessment were identified and mortality was the main clinical outcome reported. A meta-analysis showed that PEW assessed using subjective global assessment (SGA) was associated with greater mortality risk (RR: 1.99, 95% CI: 1.36–2.91). Individual nutrition parameters, such as serum chemistry, body mass, muscle mass, and dietary intakes, were not consistently associated with mortality. In conclusion, SGA is a valid tool for PEW assessment in patients with AKI, while other nutrition parameters in isolation had limited validity for PEW assessment.

1. Introduction

Acute kidney injury (AKI) is a heterogeneous group of syndromes defined by a sudden decline in glomerular filtration rate followed by an increase in serum creatinine or oliguria [1]. There are several definitions and staging systems for AKI, namely Kidney Disease Improving Global Outcomes (KDIGO) [2], Acute Kidney Injury Network [3], and Risk, Injury, Failure, Loss, and End-Stage Kidney Disease (RIFLE) [4]. The prevalence of AKI ranged from 3% to 18.3% in hospitalized adult patients and 33% to 66.7% in critically ill patients. It is estimated that less than 10% non-critically ill hospitalized patients with AKI will require kidney replacement therapy (KRT) while about 5% to 11% critically ill adults with AKI will require KRT [5]. An episode of AKI is associated with increased risk of mortality as well as long-term adverse outcomes such as new onset or worsening of chronic kidney disease (CKD), dialysis dependence, and cardiovascular disease [5,6].
Protein-energy wasting (PEW) was proposed by the International Society of Renal Nutrition and Metabolism (ISRNM) to define a state of decreased body stores of protein and energy fuels (body protein and fat masses) in patients with CKD and AKI [7]. PEW is prevalent in AKI patients and a meta-analysis of two studies reported that the prevalence of PEW in patients with AKI was 66.7% [8]. The pathogenesis of PEW in AKI is multifactorial, including metabolic alterations and impaired homeostasis responses due to sudden loss of kidney function [9], intrarenal and systemic inflammation associated with AKI [10], hypercatabolic state from the underlying comorbidity and critical illness [11], and amino acid loss in KRTs [12].
Nutritional status assessment is critical to identify patients who are PEW and at risk of mortality. The ISRNM expert panel recommends that clinical diagnosis of PEW in CKD and AKI requires at least three out of four main categories, namely biochemical criteria; low body weight, reduced total body fat, or weight loss; a decrease in muscle mass; low protein or energy intakes [7]. Subjective global assessment (SGA) has also been used for assessment of PEW [8]. These nutrition parameters have been widely used for diagnosis of PEW in patients with CKD as the relationship between these parameters and adverse outcomes in CKD is well established [13]. However, it should be noted that the context of PEW in patients with acute illness might differ from patients with chronic diseases. Therefore, the applicability and reliability of these criteria for nutritional status evaluation in AKI patients, who are often presented with fluid accumulation and deranged metabolic profile, remains unclear [14,15]. In addition, the predictive validity of these standard nutrition parameters in patients with AKI has yet to be reviewed. Therefore, the present systematic review aimed to examine the relationship of PEW and individual nutrition parameter of PEW with clinical outcomes in patients with AKI.

2. Methods

2.1. Study Protocol

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [16], and the protocol of this systematic review was registered on the International Prospective Register of Systematic Review (CRD42020168595).

2.2. Search Strategy

We performed a comprehensive search in PubMed, Scopus, and Cochrane Central Register of Controlled Trials (CENTRAL) on 12 February 2020 to identify relevant studies. Medical Subject Headings terms and free-text terms for AKI and PEW were used as the search strategy (Table S1). We also included nutrition assessment, malnutrition, and protein-energy malnutrition in our search strategy, as these terms were commonly used before the introduction of PEW in 2008 [7]. In addition, we manually search for eligible studies by checking the reference lists of relevant original articles, reviews, and guidelines from inception to February 2020. Our research was restricted to English-language studies, as it has been shown that exclusion of non-English literature does not introduce systematic bias [17].

2.3. Study Inclusion and Exclusion Criteria

Prospective cohort studies were considered eligible and included in this review if they reported the association between at least one of the readily utilizable nutritional parameter for PEW assessment (Table S2) [7] and an outcome of interest in adult patients (≥18 years old) diagnosed with AKI. Briefly, these parameters included assessment of nutritional biochemistry, body mass, muscle mass, and dietary intake. We also included studies applying SGA for PEW diagnosis, because this nutritional assessment score was validated, well-established, and had been used for PEW diagnosis in patients with AKI [8]. However, potential tools for PEW assessment such as appetite, energy expenditure, or inflammatory markers were not included in the present review as there were no definite cut-offs for these measures to diagnosis PEW [7]. The outcome measures included mortality (short-term and long-term), hospital or intensive care unit (ICU) length of stay, or renal related outcomes such as KRT dependence, KRT duration, KRT-free days, and renal recovery (either complete, partial, or absent). There was no restriction on the sample size and length of follow-up. We excluded retrospective studies due to potential bias and residual confounding. Studies involving pediatric populations, solid organ transplant recipients, patients with hepatorenal or cardiorenal syndromes, and patients with pregnancy-associated kidney disease were also excluded. In addition, we excluded studies with only univariate or receiver operating characteristic curve analyses, as other non-nutritional factors influencing the clinical outcomes should be fully adjusted in the statistical model.

2.4. Study Selection and Data Extraction

Citations from the initial search results of each database were exported to EndNote (version X7.5.3), and duplicates were removed. Two authors (B.-H.K. and H.-C.T.) screened and reviewed the titles and abstracts. Then, full texts of potential studies were retrieved and independently reviewed in details for inclusion based on pre-determined criteria. Discrepancies between two authors were resolved by discussion, and a third author (A.H.A.G.) was referred if consensus could not be reached.
One author (H.-C.T.) extracted the data from included study into a piloted sheet and another author (B.-H.K) crosschecked the extracted data. Disagreements were resolved by discussion, and a third author (A.H.A.G.) was consulted if necessary. The following data were extracted: study characteristics (country, sample size, and patient population), patients’ characteristics (age, sex, comorbidities, primary cause of AKI, requirement of KRT, type of KRT, and disease severity score), nutrition assessment for PEW, multivariable-adjusted risk estimates of clinical outcomes associated with PEW parameters such as beta coefficient (β), odds ratio (OR), hazard ratio (HR), risk ratio (RR) with their corresponding 95% confidence interval (95% CI) and/or p-value.

2.5. Assessment of Risk of Bias

Two authors (B.-H.K. and H.-C.T.) independently performed the study quality and risk of bias assessment using the Newcastle-Ottawa Scale [18]. A “star system” was used to appraise a study based on three perspectives, selection of the study cohort, comparability of the cohort, and clarity of outcome assessment and completeness of follow up. A maximum of nine stars can be given for one study.

2.6. Statistical Analysis

A meta-analysis was performed to determine the association between PEW (SGA class B and C) and mortality. The pooled risk ratio and 95% CI was calculated based on the sample size and risk ratio of each study. Heterogeneity among the studies was assessed using the chi-squared and I2 statistics, whereby a p value < 0.1 and I2 above 50% was considered having significant heterogeneity and a random effect model was used. A sensitivity analysis was performed by sequentially omitting one study at a time to verify that the overall result was not influenced by any single study. Publication bias was assessed by using Begg’s and Egger’s tests, as well as by visually inspecting the symmetry of the funnel plot. STATA software (version 16.0, StataCorp, College Station, TX, USA) was used for the analysis.

3. Results

3.1. Study Characteristics

The flowchart of study selection is presented in Figure 1. From the literature search, 4262 unique citations were identified from three databases. After screening the title and abstract, 128 studies were retrieved for full-text review. From this, 111 studies were excluded, and the reasons for exclusion are presented in Table S3. Out of the 17 studies included in the present systematic review [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35] (Table 1 and Table S4), two studies involved patients from the same cohort [19,20], but both studies were included because different nutritional parameters were reported.
Most studies (n = 11) recruited critically ill patients with AKI; two studies each recruited patients with hospitalized-acquired AKI and patients with AKI secondary to ATN, respectively; and one study each recruited elderly patients with AKI and patients from the renal intermediate care unit, respectively. The sample size ranged from 56 to 1457 patients, with only seven studies having sample size more than 200 patients. The mean or median age ranged from 58.1 to 77.9 years and 53.1 to 74.2% were male patients. The mean or median serum creatinine ranged from 158 to 522 μmol/L with three studies [27,34,35] had relatively lower serum creatinine (158–165 μmol/L), as the RIFLE criteria was used for diagnosis of AKI. All patients from six studies were receiving KRT, while the percentage of patients on KRT for 11 studies ranged from 12.1% to 67%. Patients with sepsis ranged from 17.1 to 64.3% and the mean or median C-reactive protein reported ranging from 6.6 to 26.5 mg/dL (Table S4).
For the PEW parameter, most of the studies (n = 11) had assessed serum chemistry, mainly serum albumin (n = 8), followed by serum total cholesterol (n = 4), and serum pre-albumin (n = 3). One study each had assessed the body mass index (BMI) for the body mass category and arm circumference for the muscle mass category, respectively. Six studies had evaluated dietary intake, with three studies reporting energy intake and four studies reporting protein intake. There were four studies applying SGA for diagnosis of PEW.
All studies reported mortality as the clinical outcome, while only two studies reported other clinical outcomes such as KRT-free day, ICU-free day, and hospital-free day. Five studies each reported 28-day mortality and 90-day mortality, respectively; four studies reported in-hospital mortality; and two studies each reported overall mortality and 60-day mortality, respectively. The median rate of mortality for all studies was 48% (range, 27.6 to 73.0%). In particular, the 28-, 60-, and 90-day mortality ranged from 61.4 to 73.0%, 36.0 to 50.0%, and 27.6 to 59.9%, respectively, while the in-hospital mortality ranged from 39.0 to 53.0%.

3.2. Nutritional Assessment of PEW and Clinical Outcomes

The relationships between nutritional assessments of PEW and clinical outcomes in patients with AKI are summarized in Table 2. The mean or median of serum albumin reported was ranging from 2.4 to 3.4 g/dL. Two studies showed that serum albumin was not associated with either mortality [33] or in-hospital mortality [21], whilst another two studies reported otherwise [22,31]. Contradictory findings on the association between serum albumin and 60-day mortality were noted in two studies [23,32], while one study reported a significant association between serum albumin and 28-day mortality [25]. Another study showed that serum albumin (per 0.5 g/dL decrease) was not associated with 90-day mortality [35]. For serum pre-albumin, a mean or median ranging from 13.5 to 17.6 mg/dL was reported by three studies. Gong et al. [27] showed that serum pre-albumin was not associated with mortality in elderly patients with AKI. Similarly, Xie et al. [35] also reported that serum pre-albumin (per 5 mg/dL decrease) was not associated with 90-day mortality. In contrast, Wang et al. [34] found that AKI patients with serum pre-albumin <10 mg/dL had 2.55 times increased HR for 90-day mortality. For serum total cholesterol, the mean or median reported by four studies ranged from 101 to 139 mg/dL. Two studies found no significant association between serum total cholesterol and in-hospital mortality [21,22]. Similarly, Xie et al. [35] reported that serum total cholesterol (per 3 mg/dL decrease) was not associated with 90-day mortality. Contrarily, Guimaraes et al. [28] showed that serum total cholesterol ≤96 mg/dL was associated with 28-day mortality (HR: 10.94, 95% CI: 1.89–63.29, p = 0.008).
For the body mass category, Lin et al. [30] showed that BMI was associated with mortality (OR: 0.903, 95% CI 0.840–0.971, p = 0.006) in patients with post-operative AKI receiving KRT. For the muscle mass category, one study reported that arm circumference was not associated with in-hospital mortality (OR: 0.961; 95% CI: 0.850–1.086, p = 0.52) [21].
The means of energy and protein intake ranged from 11.0 to 13.5 kcal/kg and 0.50 to 0.64 g/kg, respectively. Bellomo et al. [19,20] reported that neither energy nor protein intake was associated with 90-day mortality, KRT-free days, mechanical ventilation-free day, ICU-free days, and hospital-free day. Energy intake >25 kcal/kg/day was not associated with 28-day mortality or ICU discharge. Similarly, protein intake >1 g/kg/day was not also associated with mortality. Contrarily, two studies showed that energy intake was associated with ~5% lower risk of in-hospital mortality [21,22]. As for dietary protein intake, one study each found that protein intake was associated lower risk of in-hospital mortality (OR: 0.947; 95% CI: 0.988–0.992; p = 0.028) [22] and 28-day mortality (HR: 0.993, 95% CI: 0.987–0.999, p = 0.032) [24], respectively. However, it is important to note that the upper limits of 95% CI of these studies [21,22,24] were very close to 1.00, therefore, the clinical significance remains unclear. Kritmetapak et al. [29] also showed that dietary protein (per 0.2 g/kg increase) was associated with survival on 28th day (OR: 4.62; 95% CI: 1.48–14.47; p = 0.009). It is also worth highlighting that the analyses by Bellomo et al. [19,20] included adjustment with more prognostic covariates, whereas the statistical analyses of other studies [22,24,29] were considered minimally adjusted.
There were four studies reporting the prevalence of PEW based on SGA in patients with AKI (Table 3). The prevalence of severely malnourished patients was highest (41.7%) in the intermediate care unit [26], while 41.7–68.8% patients from ICU and/or wards were mildly/moderately malnourished [21,28,29]. The meta-analysis of these four studies showed that PEW (SGA class B or C) was associated with increased mortality (RR: 1.99, 95% CI: 1.36–2.91) in patients with AKI (Figure 2). The sensitivity analysis showed that exclusion of each of the studies did not affect the overall direction and magnitude of the result, suggesting that the result was stable and not driven by any single study (Figure S1). The Egger’s test (p = 0.748) and Begg’s test (p = 0.497) as well as visual inspection of the funnel plot (Figure S2) showed no evidence of publication bias.

3.3. Quality Assessment

Based on the Newcastle-Ottawa Scale assessment, six studies were rated with 9 stars, three studies were rated with 8 stars, five studies were rated with 7 stars, two studies were rated with 6 stars, and one study was rated with 5 stars (Table S5). Nine studies (52.9%) rated with 8 or 9 stars were considered as a low risk of bias. Majority of the studies did not report the detailed process of patient recruitment and duration or completeness of follow-up. In addition, some studies had performed minimal statistical adjustments for the predictive validity analyses.

4. Discussion

This systematic review set out with the aim to examine the association between nutritional assessments of PEW and clinical outcomes in patients with AKI. We observed a high prevalence of PEW (ranging from 67.9 to 82.1%) assessed via SGA, and PEW was associated with almost two times greater risk of mortality. However, our literature search identified no study applying the ISRNM criteria for PEW diagnosis in patients with AKI, which could be related to the limited feasibility and applicability. As we assessed each individual nutritional parameter of PEW, there was inconsistent evidence on the associations between these parameters and clinical outcomes in patients with AKI. The PEW criteria proposed by the ISRNM are mainly derived from data obtained in patients with CKD. Therefore, the cut-off values may not be relevant for patients with AKI experiencing drastic deterioration in nutritional status. Further validation for the PEW diagnostic criteria by the ISRNM in patients with AKI remains necessary.
Serum albumin was the most frequently reported nutritional biomarker, as it is relatively inexpensive and widely available, though serum pre-albumin is considered more sensitive due to its shorter half-life (2–3 days) than serum albumin (20 days) [37]. Although the synthesis of albumin and pre-albumin is influenced by dietary protein intakes, non-nutritional factors such as inflammation, overhydration, physiological stress, and infection are also implicated in low levels of serum albumin or pre-albumin [37]. Epidemiological studies have consistently shown that low levels of serum albumin and pre-albumin are strongly associated with poor clinical outcomes in dialysis patients [7,38,39]. However, patients with AKI are generally presented with a more profound hypoalbuminemia or hypoprealbuminemia compared to CKD patients on dialysis, due to a greater degree of underlying inflammatory response during acute illness. In the present review, it was observed that the mean or median serum albumin levels of patients with AKI were much lower than normal values, which was attributed to sepsis and accompanying systemic inflammation. During acute illness, the distribution of serum albumin between the intravascular and extravascular compartments is altered due to increased capillary leakage. In addition, the rate of albumin synthesis is reduced, while the albumin degradation rate is increased in the presence of critical illness [40]. Therefore, hypoalbuminemia is prevalent at the early phase of acute illness and its concentration will only increase during the recovery phase. Although a meta-analysis by Wiedermann [41] showed that hypoalbuminemia is a significant predictor of mortality in patients with AKI, this meta-analysis included studies up to year 2009 only and was limited by inclusion of studies with retrospective design. Serum pre-albumin below 30 mg/dL is indicative as PEW in dialysis patients [7]; Wang et al. [34] showed that only AKI patients with a serum pre-albumin level below 10 mg/dL had a significantly higher 90-day mortality risk. Serum albumin and pre-albumin level in patients with AKI, particularly those with critical illness may reflect the severity of illness instead of caloric and protein deficits [42]. Therefore, these biomarkers alone are not reliable in diagnosing PEW in AKI patients. In fact, serum albumin and pre-albumin are not included in the standardized diagnostic criteria for malnutrition proposed by the Academy of Nutrition and Dietetics/American Society for Parenteral and Enteral Nutrition [43], while the Global Leadership Initiative Malnutrition suggests that serum albumin and pre-albumin may be used as a supportive proxy measure of inflammation [44].
Serum cholesterol is a parameter of malnutrition that has been included in several nutritional screening and assessment tools [36]. A meta-analysis demonstrated that serum cholesterol was associated with the risk of malnutrition in older adults with or without acute diseases [45]. Hypocholesterolemia is paradoxically associated with reduced risk of mortality in patients on maintenance hemodialysis [46], attributed to the cholesterol-lowering effect of systemic inflammation and malnutrition [47]. Similar to other visceral proteins, hypocholesterolemia had been documented in critically injured patients, which was correlated with organ dysfunction and presence of infections [48].
Evaluation of body mass and muscle mass using anthropometric measures and physical examination are important diagnostic criteria of PEW [7]. BMI is the most widely used indicator of body mass and has been shown to be paradoxically associated with mortality in CKD patients on dialysis [49]. The obesity paradox observed in patients with renal insufficiency may be explained by higher plasma levels of protective mediators, a greater hemodynamic stability during KRT, and adipose tissue acting as a “buffer” for uremic toxins [50]. Lin et al. [30] reported that BMI was significantly associated with lower 90-day mortality in patients with postoperative AKI in ICU. It should be noted that this population had a relatively normal mean BMI (~23.5 kg/m2), therefore this finding should be interpreted as potential harm associated with lower BMI rather than survival benefit of obesity. Schiffl [51] reviewed eight retrospective studies, which showed conflicting findings on the association between BMI and mortality in critically ill patients with AKI, and the author suggested that the obesity paradox observed in patients with AKI could be attributed to statistical fallacy and the result of chance, bias, and residual confounding variables in retrospective cohort analyses. Essentially, PEW occurs at any BMI and unintentional weight loss should also be considered as an important indicator of PEW [7]. In the context of acute illness, unintentional weight loss of more than 1% within a week should be suggestive of PEW [43], but assessment of weight loss in patients with AKI is challenging as weight changes are often masked with fluid retention.
Patients with AKI experience major metabolic alterations, which lead to muscle wasting, a fundamental feature of PEW. Objective and feasible assessment of muscle mass is essential for diagnosis of PEW. Mid-arm muscle circumference is a measured surrogate of lean body mass that has been shown to be a significant predictor of survival in patients on maintenance hemodialysis [52]. However, Berbel et al. [21] reported that arm muscle circumference was not associated with mortality in patients with AKI. Measurement of arm circumference is not sensitive to identify muscle wasting during acute illness [53], and the accuracy and practicability of this anthropometric measurement in sedated or bed-ridden patients with edema is uncertain. Sabatino et al. [54] proposed that ultrasound imaging of quadriceps muscle is a reliable and non-invasive method for evaluation of skeletal muscle in patients with AKI, and this method had been validated against the computerized tomography scan [55]. Further studies investigating the potential utility of this muscle assessment method in patients with AKI are warranted.
Suboptimal nutritional intake is one of the contributory factors to development of PEW. The nutritional requirements of patients with AKI are affected by disease severity, pre-existing nutritional status, underlying co-morbidities, and KRT modality. The clinical practice guidelines have recommended energy and protein intakes of 20–30 kcal/kg/day and 1.2–2.0 g/kg/day for patients with AKI, respectively [2,56]. However, the present review showed that the means of energy and protein intake among patients with AKI were much lower than the recommended amount [19,20,21,22,24,29]. There was inconclusive evidence on the association between energy and protein intake with clinical outcomes in patients with AKI, and those studies that reported higher mortality risk in patients with low energy and protein intakes had limitations with the statistical models that were not fully adjusted. Meta-analyses of randomized controlled trials have demonstrated that energy and protein provisions were not associated with clinical outcomes in critically ill patients [57,58], though data specific to AKI patients was lacking. Hypocaloric nutrition is suggested at the early phase of critical illness to avoid overfeeding as substantial energy is produced endogenously via substrate mobilization [59]. In preclinical studies, energy restriction has been shown to exert renoprotective effects during AKI [60]. Although a greater amount of protein provision is recommended to achieve positive nitrogen balance, particularly in AKI patients undergoing KRTs [56], high protein intakes are potentially associated with negative metabolic complications and poorer clinical outcomes [61,62]. Future work is required to determine optimal energy and protein provision to patients with AKI.
The present systematic review has several limitations. Firstly, this systematic review included observational studies, which should be interpreted as an association and do not necessarily imply causality. Secondly, meta-analyses of individual parameters of PEW cannot be performed due to the heterogeneity in outcomes reported (in-hospital mortality, 28-day mortality, or 90-day mortality, etc.) and expressed (OR, RR, or HR). Thirdly, some studies were not designed to determine the prognostic ability of these nutritional parameters as the primary objective, therefore their results should be interpreted with caution. In addition, these studies recruited patients from hospital or ICU, therefore the findings should not be generalized to patients with community-acquired AKI. Lastly, we also cannot determine the association of PEW criteria with other clinical outcomes such as ICU or hospital length of stay, renal recovery, quality of life, and physical function due to lack of studies that reported these outcomes.

5. Conclusions

SGA is a valid tool for assessment of PEW in patients with AKI, as it has been demonstrated to be associated with increased mortality risk. Individual nutrition parameters for PEW assessment in isolation did not have consistent prognostic validity with clinical outcomes in patients with AKI. Serum proteins by themselves are not reliable nutrition markers for guiding and monitoring nutrition prescription in AKI patients with critical illness. On the other hand, there is a critical need for further experimental investigations on the body and muscle mass criteria to assess PEW in patients with AKI. Further studies are also warranted to examine whether AKI patients diagnosed with PEW will be benefited from aggressive nutrition therapy.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6643/12/9/2809/s1, Table S1: Full search strategy, Table S2: Protein-energy wasting diagnostic criteria, Table S3: Study selection based on inclusion criteria after reviewing full text, Table S4: Summary of studies included in the review (additional information), Table S5: Quality assessment of studies included in the review, Figure S1: Sensitivity analysis, Figure S2: Funnel plot.

Author Contributions

Conceptualization, B.-H.K. and A.H.A.G.; data curation, B.-H.K., H.-C.T.; statistical analysis, S.C.T.; original draft preparation, B.-H.K.; writing—review and editing, H.-C.T., S.C.T., R.A.R., A.H.A.G. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Universiti Kebangsaan Malaysia (MI-2020-004).

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Levey, A.S.; James, M.T. Acute kidney injury. Ann. Intern. Med. 2017, 167, ITC66–ITC80. [Google Scholar] [CrossRef] [PubMed]
  2. Kellum, J.A.; Lameire, N.; Aspelin, P.; Barsoum, R.S.; Burdmann, E.A.; Goldstein, S.L.; Herzog, C.A.; Joannidis, M.; Kribben, A.; Levey, A.S.; et al. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for acute kidney injury. Kidney Int. Suppl. 2012, 2, 1–138. [Google Scholar]
  3. Mehta, R.L.; Kellum, J.A.; Shah, S.V.; Molitoris, B.A.; Ronco, C.; Warnock, D.G.; Levin, A. Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit. Care 2007, 11, R31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Bellomo, R.; Ronco, C.; Kellum, J.A.; Mehta, R.L.; Palevsky, P. Acute renal failure–definition, outcome measures, animal models, fluid therapy and information technology needs: The second international consensus conference of the acute dialysis quality initiative (adqi) group. Crit. Care 2004, 8, R204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Hoste, E.A.; Kellum, J.A.; Selby, N.M.; Zarbock, A.; Palevsky, P.M.; Bagshaw, S.M.; Goldstein, S.L.; Cerdá, J.; Chawla, L.S. Global epidemiology and outcomes of acute kidney injury. Nat. Rev. Nephrol. 2018, 14, 607–625. [Google Scholar] [CrossRef]
  6. Doyle, J.F.; Forni, L.G. Acute kidney injury: Short-term and long-term effects. Crit. Care 2016, 20, 188. [Google Scholar] [CrossRef] [Green Version]
  7. Fouque, D.; Kalantar-Zadeh, K.; Kopple, J.; Cano, N.; Chauveau, P.; Cuppari, L.; Franch, H.; Guarnieri, G.; Ikizler, T.; Kaysen, G.; et al. A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease. Kidney Int. 2008, 73, 391–398. [Google Scholar] [CrossRef] [Green Version]
  8. Carrero, J.J.; Thomas, F.; Nagy, K.; Arogundade, F.; Avesani, C.M.; Chan, M.; Chmielewski, M.; Cordeiro, A.C.; Espinosa-Cuevas, A.; Fiaccadori, E.; et al. Global prevalence of protein-energy wasting in kidney disease: A meta-analysis of contemporary observational studies from the international society of renal nutrition and metabolism. J. Ren. Nutr. 2018, 28, 380–392. [Google Scholar] [CrossRef]
  9. Fiaccadori, E.; Maggiore, U.; Cabassi, A.; Morabito, S.; Castellano, G.; Regolisti, G. Nutritional evaluation and management of aki patients. J. Ren. Nutr. 2013, 23, 255–258. [Google Scholar] [CrossRef]
  10. Rabb, H.; Griffin, M.D.; McKay, D.B.; Swaminathan, S.; Pickkers, P.; Rosner, M.H.; Kellum, J.A.; Ronco, C. Inflammation in aki: Current understanding, key questions, and knowledge gaps. J. Am. Soc. Nephrol. 2016, 27, 371–379. [Google Scholar] [CrossRef] [Green Version]
  11. Bufarah, M.N.B.; de Góes, C.R.; de Oliveira, M.C.; Ponce, D.; Balbi, A.L. Estimating catabolism: A possible tool for nutritional monitoring of patients with acute kidney injury. J. Ren. Nutr. 2017, 27, 1–7. [Google Scholar] [CrossRef] [Green Version]
  12. Patel, J.J.; McClain, C.J.; Sarav, M.; Hamilton-Reeves, J.; Hurt, R.T. Protein requirements for critically ill patients with renal and liver failure. Nutr. Clin. Pract. 2017, 32, 101S–111S. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Lodebo, B.T.; Shah, A.; Kopple, J.D. Is it important to prevent and treat protein-energy wasting in chronic kidney disease and chronic dialysis patients? J. Ren. Nutr. 2018, 28, 369–379. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Fiaccadori, E.; Cremaschi, E.; Regolisti, G. Nutritional assessment and delivery in renal replacement therapy patients. Semin. Dial. 2011, 24, 169–175. [Google Scholar] [CrossRef]
  15. McCarthy, M.S.; Phipps, S.C. Special nutrition challenges: Current approach to acute kidney injury. Nutr. Clin. Pract. 2014, 29, 56–62. [Google Scholar] [CrossRef]
  16. Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.; Kleijnen, J.; Moher, D. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med. 2009, 6, e1000100. [Google Scholar] [CrossRef]
  17. Morrison, A.; Polisena, J.; Husereau, D.; Moulton, K.; Clark, M.; Fiander, M.; Mierzwinski-Urban, M.; Clifford, T.; Hutton, B.; Rabb, D. The effect of English-language restriction on systematic review-based meta-analyses: A systematic review of empirical studies. Int. J. Technol. Assess. Health Care 2012, 28, 138. [Google Scholar] [CrossRef] [PubMed]
  18. Newcastle-Ottawa Quality Assessment Scale: Case Control Studies. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed on 14 February 2020).
  19. Bellomo, R.; Cass, A.; Cole, L.; Finfer, S.; Gallagher, M.; Lee, J.; Lo, S.; McArthur, C.; McGuinness, S.; Myburgh, J. Calorie intake and patient outcomes in severe acute kidney injury: Findings from the randomized evaluation of normal vs. Augmented level of replacement therapy (renal) study trial. Crit. Care 2014, 18, R45. [Google Scholar] [CrossRef] [Green Version]
  20. Bellomo, R.; Cass, A.; Cole, L.; Finfer, S.; Gallagher, M.; Lee, J.; Lo, S.; McArthur, C.; McGuinness, S.; Norton, R. Daily protein intake and patient outcomes in severe acute kidney injury: Findings of the randomized evaluation of normal versus augmented level of replacement therapy (renal) trial. Blood Purif. 2014, 37, 325–334. [Google Scholar] [CrossRef]
  21. Berbel, M.N.; de Goes, C.R.; Balbi, A.L.; Ponce, D. Nutritional parameters are associated with mortality in acute kidney injury. Clinics 2014, 69, 476–482. [Google Scholar] [CrossRef]
  22. Bufarah, M.; Costa, N.; Losilla, M.; Reis, N.; Silva, M.; Balbi, A.; Ponce, D. Low caloric and protein intake is associated with mortality in patients with acute kidney injury. Clin. Nutr. ESPEN 2018, 24, 66–70. [Google Scholar] [CrossRef] [PubMed]
  23. Chertow, G.M.; Lazarus, J.M.; Paganini, E.P.; Allgren, R.L.; Lafayette, R.A.; Sayegh, M.H. Predictors of mortality and the provision of dialysis in patients with acute tubular necrosis. The Auriculin Anaritide Acute Renal Failure Study Group. J. Am. Soc. Nephrol. 1998, 9, 692–698. [Google Scholar] [PubMed]
  24. De Góes, C.R.; Balbi, A.L.; Ponce, D. Evaluation of factors associated with hypermetabolism and hypometabolism in critically ill aki patients. Nutrients 2018, 10, 505. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Demirjian, S.; Teo, B.W.; Guzman, J.A.; Heyka, R.J.; Paganini, E.P.; Fissell, W.H.; Schold, J.D.; Schreiber, M.J. Hypophosphatemia during continuous hemodialysis is associated with prolonged respiratory failure in patients with acute kidney injury. Nephrol. Dial. Transplant. 2011, 26, 3508–3514. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  26. Fiaccadori, E.; Lombardi, M.; Leonardi, S.; Rotelli, C.F.; Tortorella, G.; Borghetti, A. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: A prospective cohort study. J. Am. Soc. Nephrol. 1999, 10, 581–593. [Google Scholar]
  27. Gong, Y.; Zhang, F.; Ding, F.; Gu, Y. Elderly patients with acute kidney injury (aki): Clinical features and risk factors for mortality. Arch. Gerontol. Geriatr. 2012, 54, e47–e51. [Google Scholar] [CrossRef]
  28. Guimarães, S.M.; Lima, E.Q.; Cipullo, J.P.; Lobo, S.M.; Burdmann, E.A. Low insulin-like growth factor-1 and hypocholesterolemia as mortality predictors in acute kidney injury in the intensive care unit. Crit. Care Med. 2008, 36, 3165–3170. [Google Scholar] [CrossRef]
  29. Kritmetapak, K.; Peerapornratana, S.; Srisawat, N.; Somlaw, N.; Lakananurak, N.; Dissayabutra, T.; Phonork, C.; Leelahavanichkul, A.; Tiranathanagul, K.; Susantithapong, P.; et al. The impact of macro-and micronutrients on predicting outcomes of critically ill patients requiring continuous renal replacement therapy. PLoS ONE 2016, 11, e0156634. [Google Scholar] [CrossRef]
  30. Lin, Y.-F.; Ko, W.-J.; Chu, T.-S.; Chen, Y.-S.; Wu, V.-C.; Chen, Y.-M.; Wu, M.-S.; Chen, Y.-W.; Tsai, C.-W.; Shiao, C.-C.; et al. The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy. Am. J. Surg. 2009, 198, 325–332. [Google Scholar] [CrossRef]
  31. Lins, R.; Elseviers, M.; Daelemans, R.; Zachée, P.; Zachée, P.; Gheuens, E.; Lens, S.; De Broe, M. Prognostic value of a new scoring system for hospital mortality in acute renal failure. Clin. Nephrol. 2000, 53, 10–17. [Google Scholar]
  32. Mendu, M.L.; Ciociolo, G.R.; McLaughlin, S.R.; Graham, D.A.; Ghazinouri, R.; Parmar, S.; Grossier, A.; Rosen, R.; Laskowski, K.R.; Riella, L.V.; et al. A decision-making algorithm for initiation and discontinuation of rrt in severe aki. Clin. J. Am. Soc. Nephrol. 2017, 12, 228–236. [Google Scholar] [CrossRef] [PubMed]
  33. Sezer, M.T.; Demir, M.; Gungor, G.; Yavuz, L. Relevance of nutritional route and intercellular adhesion molecule-1 in patients with acute renal failure and its prognostic implications. J. Ren. Nutr. 2008, 18, 288–293. [Google Scholar] [CrossRef] [PubMed]
  34. Wang, W.; Pan, Y.; Tang, X.; Hao, G.; Xie, Y.; Ma, S.; Luo, J.; Guo, D.; Ding, F. Serum prealbumin and its changes over time are associated with mortality in acute kidney injury. Sci. Rep. 2017, 7, 1–11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Xie, Q.; Zhou, Y.; Xu, Z.; Yang, Y.; Kuang, D.; You, H.; Ma, S.; Hao, C.; Gu, Y.; Lin, S.; et al. The ratio of crp to prealbumin levels predict mortality in patients with hospital-acquired acute kidney injury. BMC Nephrol. 2011, 12, 30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Keller, U. Nutritional laboratory markers in malnutrition. J. Clin. Med. 2019, 8, 775. [Google Scholar] [CrossRef] [Green Version]
  38. Mittman, N.; Avram, M.M.; Oo, K.K.; Chattopadhyay, J. Serum prealbumin predicts survival in hemodialysis and peritoneal dialysis: 10 years of prospective observation. Am. J. Kidney Dis. 2001, 38, 1358–1364. [Google Scholar] [CrossRef]
  39. Rambod, M.; Kovesdy, C.P.; Bross, R.; Kopple, J.D.; Kalantar-Zadeh, K. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am. J. Clin. Nutr. 2008, 88, 1485–1494. [Google Scholar] [CrossRef] [Green Version]
  40. Nicholson, J.P.; Wolmarans, M.R.; Park, G.R. The role of albumin in critical illness. Br. J. Anaesth. 2000, 85, 599–610. [Google Scholar] [CrossRef] [Green Version]
  41. Wiedermann, C.J.; Wiedermann, W.; Joannidis, M. Hypoalbuminemia and acute kidney injury: A meta-analysis of observational clinical studies. Intensive Care Med. 2010, 36, 1657–1665. [Google Scholar] [CrossRef]
  42. Yeh, D.D.; Johnson, E.; Harrison, T.; Kaafarani, H.M.; Lee, J.; Fagenholz, P.; Saillant, N.; Chang, Y.; Velmahos, G. Serum levels of albumin and prealbumin do not correlate with nutrient delivery in surgical intensive care unit patients. Nutr. Clin. Pract. 2018, 33, 419–425. [Google Scholar] [CrossRef] [PubMed]
  43. White, J.V.; Guenter, P.; Jensen, G. ASPEN Malnutrition Task Force. Consensus statement: Academy of Nutrition and Dietetics and American Society for Parenteral and Enteral Nutrition: Characteristics recommended for the identification and documentation of adult malnutrition (undernutrition). JPEN J. Parenter. Enter. Nutr. 2012, 36, 275–283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Cederholm, T.; Jensen, G.L.; Correia, M.I.; Gonzalez, M.C.; Fukushima, R.; Higashiguchi, T.; Baptista, G.; Barazzoni, R.; Blaauw, R.; Coats, A.; et al. GLIM criteria for the diagnosis of malnutrition—A consensus report from the global clinical nutrition community. J. Cachexia Sarcopenia Muscle 2019, 10, 207–217. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Zhang, Z.; Pereira, S.L.; Luo, M.; Matheson, E.M. Evaluation of blood biomarkers associated with risk of malnutrition in older adults: A systematic review and meta-analysis. Nutrients 2017, 9, 829. [Google Scholar] [CrossRef]
  46. Kilpatrick, R.D.; McAllister, C.J.; Kovesdy, C.P.; Derose, S.F.; Kopple, J.D.; Kalantar-Zadeh, K. Association between serum lipids and survival in hemodialysis patients and impact of race. J. Am. Soc. Nephrol. 2007, 18, 293–303. [Google Scholar] [CrossRef] [Green Version]
  47. Liu, Y.; Coresh, J.; Eustace, J.A.; Longenecker, J.C.; Jaar, B.; Fink, N.E.; Tracy, R.P.; Powe, N.R.; Klag, M.J. Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA J. Am. Med. Assoc. 2004, 291, 451–459. [Google Scholar] [CrossRef] [Green Version]
  48. Dunham, C.; Fealk, M.H.; Sever, W.E. Following severe injury, hypocholesterolemia improves with convalescence but persists with organ failure or onset of infection. Crit. Care 2003, 7, R145. [Google Scholar] [CrossRef] [Green Version]
  49. Rahimlu, M.; Shab-Bidar, S.; Djafarian, K. Body mass index and all-cause mortality in chronic kidney disease: A dose–response meta-analysis of observational studies. J. Ren. Nutr. 2017, 27, 225–232. [Google Scholar] [CrossRef] [Green Version]
  50. Schetz, M.; De Jong, A.; Deane, A.M.; Druml, W.; Hemelaar, P.; Pelosi, P.; Pickkers, P.; Reintam-Blaser, A.; Roberts, J.; Sakr, Y.; et al. Obesity in the critically ill: A narrative review. Intensive Care Med. 2019, 45, 757–769. [Google Scholar] [CrossRef]
  51. Schiffl, H. Obesity and the Survival of Critically Ill Patients with Acute Kidney Injury: A Paradox within the Paradox? Kidney Dis. 2020, 6, 13–21. [Google Scholar] [CrossRef]
  52. Noori, N.; Kopple, J.D.; Kovesdy, C.P.; Feroze, U.; Sim, J.J.; Murali, S.B.; Luna, A.; Gomez, M.; Luna, C.; Bross, R.; et al. Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2010, 5, 2258–2268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  53. Reid, C.L.; Campbell, I.T.; Little, R.A. Muscle wasting and energy balance in critical illness. Clin. Nutr. 2004, 23, 273–280. [Google Scholar] [CrossRef]
  54. Sabatino, A.; Regolisti, G.; Bozzoli, L.; Fani, F.; Antoniotti, R.; Maggiore, U.; Fiaccadori, E. Reliability of bedside ultrasound for measurement of quadriceps muscle thickness in critically ill patients with acute kidney injury. Clin. Nutr. 2017, 36, 1710–1715. [Google Scholar] [CrossRef] [PubMed]
  55. Sabatino, A.; Regolisti, G.; Di Mario, F.; Ciuni, A.; Palumbo, A.; Peyronel, F.; Maggiore, U.; Fiaccadori, E. Validation by CT scan of quadriceps muscle thickness measurement by ultrasound in acute kidney injury. J. Nephrol. 2020, 33, 109–117. [Google Scholar] [CrossRef] [PubMed]
  56. McClave, S.A.; Taylor, B.E.; Martindale, R.; Warren, M.M.; Johnson, D.R.; Braunschweig, C.; McCarthy, M.S.; Davanos, E.; Rice, T.W.; Cresci, G.A.; et al. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). JPEN J. Parenter. Enter. Nutr. 2016, 40, 159–211. [Google Scholar] [CrossRef] [PubMed]
  57. Fetterplace, K.; Gill, B.M.; Chapple, L.A.; Presneill, J.J.; MacIsaac, C.; Deane, A.M. Systematic Review With Meta-Analysis of Patient-Centered Outcomes, Comparing International Guideline–Recommended Enteral Protein Delivery With Usual Care. JPEN J. Parenter. Enter. Nutr. 2020, 44, 610–620. [Google Scholar] [CrossRef] [PubMed]
  58. Al-Dorzi, H.M.; Albarrak, A.; Ferwana, M.; Murad, M.H.; Arabi, Y.M. Lower versus higher dose of enteral caloric intake in adult critically ill patients: A systematic review and meta-analysis. Crit. Care. 2016, 20, 358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  59. Singer, P.; Blaser, A.R.; Berger, M.M.; Alhazzani, W.; Calder, P.C.; Casaer, M.P.; Hiesmayr, M.; Mayer, K.; Montejo, J.C.; Pichard, C.; et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin. Nutr. 2019, 38, 48–79. [Google Scholar] [CrossRef] [Green Version]
  60. Wang, S.Y.; Cai, G.Y.; Chen, X.M. Energy restriction in renal protection. Br. J. Nutr. 2018, 120, 1149–1158. [Google Scholar] [CrossRef] [Green Version]
  61. Arabi, Y.M.; Al-Dorzi, H.M.; Sadat, M. Protein intake and outcome in critically ill patients. Curr. Opin. Clin. Nutr. 2020, 23, 51–58. [Google Scholar] [CrossRef]
  62. Heyland, D.K.; Stapleton, R.; Compher, C. Should we prescribe more protein to critically ill patients? Nutrients 2018, 10, 462. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Nutrients 12 02809 g001 550
Figure 1. Preferred reporting items for systematic reviews and meta-analyses study flow for literature search and study selection process. Abbreviations: AKI, acute kidney injury; PEW, protein-energy wasting.
Figure 1. Preferred reporting items for systematic reviews and meta-analyses study flow for literature search and study selection process. Abbreviations: AKI, acute kidney injury; PEW, protein-energy wasting.
Nutrients 12 02809 g001
Nutrients 12 02809 g002 550
Figure 2. Pooled risk ratio for the association of protein-energy wasting with mortality in patients with acute kidney injury.
Figure 2. Pooled risk ratio for the association of protein-energy wasting with mortality in patients with acute kidney injury.
Nutrients 12 02809 g002
Table
Table 1. Summary of studies included in the review.
Table 1. Summary of studies included in the review.
Author, YearCountryPopulationnMale, n (%)Age (Year)SCr (μmol/L)Sepsis (%)KRT (%)Mortality Rate (%)PEW and Nutrition ParameterClinical Outcome
Bellomo 2014 [19,20]Australia, New ZealandCritical ill1457941 (64.6)65.133549.310044.6Energy intake, protein intake28-day mortality, 90-day mortality, KRT-free day, ICU-free day, hospital-free day
Berbel, 2014 [21]BrazilATN13391 (68.4)61.135931.057.844.5Albumin, total cholesterol, arm circumference, energy intake, SGAIn-hospital mortality
Bufarah, 2018 [22]BrazilATN595384 (64.5)64.0301NA52.046.0Albumin, total cholesterol, energy intake, protein intakeIn-hospital mortality
Chertow, 1998 [23]United StatesCritical ill, ATN256166 (65.0)62.040730.020.036.3Albumin60-day mortality
de Goes, 2018 [24]BrazilCritical ill, ATN12486 (69.4)61.138947.610073.0Protein intake28-day mortality
Demirjian, 2011 [25]United StatesCritical ill321209 (65.1)59.0362NA10066.0Albumin28-day mortality
Fiaccadori, 1999 [26]ItalyAKI patients in RICU309197 (63.8)67.052223.367.039.0SGAIn-hospital mortality
Gong, 2012 [27]ChinaElderly (≥ 65 years old)9962 (62.6)77.916529.312.142.4Pre-albuminMortality
Guimaraes, 2008 [28]BrazilCritical ill5636 (64.3)58.129264.323.269.6Total cholesterol, SGA28-day mortality
Kritmetapak, 2016 [29]ThailandCritical ill7047 (67.1)60.7316NA10061.4Protein intake, SGA28-day mortality
Lin, 2009 [30]TaiwanCritical ill, post-operative342204 (59.6)64.0292NA10059.9Body mass index90-day mortality
Lins, 2000 [31]BelgiumCritical ill197119 (60.4)69.8380NA26.053.0AlbuminIn-hospital mortality
Mendu, 2017 [32]United StatesCritical ill176102 (58.0)61.0301NA49.050.0Albumin60-day mortality
Sezer, 2008 [33]TurkeyCritical ill6434 (53.1)63.7NANA20.050.0AlbuminMortality
Wang, 2017 [34]ChinaHospital acquired AKI340247 (72.6)62.515817.113.827.6Prealbumin90-day mortality
Xie, 2011 [35]ChinaHospital acquired AKI155115 (74.2)63.416543.819.433.5Albumin, prealbumin, total cholesterol90-day mortality
AKI, acute kidney injury; ATN, acute tubular necrosis; ICU, intensive care unit; KRT, kidney replacement therapy; NA, not available; PEW, protein-energy wasting; RICU, renal intermediate care unit; SCr, serum creatinine; SGA, subjective global assessment.
Table
Table 2. Nutrition parameters and clinical outcomes.
Table 2. Nutrition parameters and clinical outcomes.
StudyMean ± SD/Median (IQR)Results
Serum chemistry
Serum albumin
Sezer, 2008 [33]3.2 ± 0.8 g/dLSerum albumin was not associated with mortality (β = 0.247, 95% CI: 0.047–1.304, p = 0.100)
Berbel, 2014 [21]2.4 g/dL *Serum albumin was not associated with in-hospital mortality (OR: 0.436, 95% CI: 0.124–1.528, p = 0.19)
Bufarah, 2018 [22]2.4 g/dL *Higher serum albumin was associated with lower in-hospital mortality (OR: 0.545, 95% CI: 0.401–0.417, p < 0.001)
Lins, 2000 [31]3.2 ± 0.9 g/dLLower serum albumin was associated with higher in-hospital mortality (RR: 1.50, 95% CI: 1.14–1.97)
Demirjian, 2011 [25]2.4 ± 0.7 g/dLHigher serum albumin was associated with lower 28-day mortality (HR: 0.76, 95% CI: 0.59–0.98, p = 0.04)
Mendu, 2017 [32]2.5 ± 0.6 g/dLHigher serum albumin was associated with lower 60-day mortality (OR: 0.49, 95% CI: 0.27–0.89, p = 0.02)
Chertow, 1998 [23]2.7 ± 0.7 g/dLSerum albumin (per g/dL) was not associated with 60-day mortality (RR: 0.73, 95% CI: 0.51–1.04, p = 0.08)
Xie, 2011 [35]3.2 ± 0.7 g/dLSerum albumin (per 0.5 g/dL decrease) was not associated with 90-day mortality (HR: 0.967, p = 0.737)
Serum prealbumin
Gong, 2012 [27]13.5 (7.7) mg/dLSerum prealbumin was not associated with mortality (OR: 0.328, 95% CI: 0.095–1.135, p = 0.078)
Wang, 2017 [34]17.6 ± 6.9 mg/dLSerum prealbumin <10 mg/dL was associated with greater 90-day mortality (HR: 2.55, 95% CI: 1.18–5.49, p = 0.02)
Xie, 2011 [35]15.1 ± 6.8 mg/dLSerum prealbumin (per 5 mg/dL decrease) was not associated with 90-day mortality (HR: 1.099, p = 0.414)
Serum total cholesterol
Berbel, 2014 [21]125 mg/dL *Serum total cholesterol was not associated with in-hospital mortality (OR: 1.005, 95% CI: 0.997–1.013, p = 0.19)
Burfarah, 2008 [22]119 mg/dL *Serum total cholesterol was not associated with in-hospital mortality (OR: 0.995, 95% CI: 0.991–1.000, p = 0.052)
Guimaraes, 2008 [28]101 ± 52 mg/dLSerum total cholesterol ≤ 96 mg/dL was associated with higher 28-day mortality (HR: 10.94, 95% CI: 1.89–63.29, p = 0.008)
Xie, 2011 [35]139 ± 58 mg/dLA decrease of 3 mg/dL in serum total cholesterol was not associated with 90-day mortality (HR: 0.949, p = 0.470)
Body mass
Body mass index
Lin, 2009 [30]23.5 ± 3.8 kg/m2Higher body mass index was associated with lower mortality (OR: 0.903, 95% CI 0.840–0.971, p = 0.006).
Muscle mass
Arm circumference
Berbel, 2014 [21]29.9 ± 5.4 cm *Arm circumference was not associated with in-hospital mortality (OR: 0.961; 95% CI: 0.850–1.086, p = 0.52)
Dietary intake
Energy intake
Bellomo, 2014 [19]11.0 ± 9.0 kcal/kgEnergy intake was not associated with 90-day mortality (OR: 1.079, 95% CI: 0.55–2.13, p = 0.8275), KRT free days (p = 0.2695), ICU-free days (p = 0.4714), and hospital free days (p = 0.5625).
Berbel, 2014 [21]12.1 kcal/kg *Higher energy intake was associated with lower in-hospital mortality (OR: 0.950, 95% CI: 0.910–0.991, p = 0.020)
Bufarah, 2018 [22]13.5 kcal/kg *Higher energy intake was associated with lower in-hospital mortality (OR: 0.946, 95% CI: 0.901–0.994; p = 0.029)
Protein intake
Bellomo, 2014 [20]0.50 ± 0.40 g/kgProtein intake was not associated with 90-day mortality (OR: 0.998, 95% CI: 0.99–1.01, p = 0.6413), KRT-free days (p = 0.5792), MV-free days (p = 0.7564), ICU-free days (p = 0.6801), and hospital-free days (p = 0.5991)
Bufarah, 2018 [22]0.64 g/kg *Higher protein intake was associated with lower in-hospital mortality (OR: 0.947; 95% CI: 0.988–0.992; p = 0.028)
de Goes, 2018 [24]31.5 g *Higher protein intake was associated with lower 28-day mortality (HR: 0.993, 95% CI: 0.987–0.999, p = 0.032)
Kritmetapak, 2016 [29]0.62 ± 0.30 g/kgHigher protein intake (per 0.2 g/kg) was associated with greater survival at day-28 (OR: 4.62; 95% CI: 1.48–14.47; p = 0.009)
CI, confidence interval; ICU, intensive care unit; IQR, interquartile range; HR, hazard ratio; KRT, kidney replacement therapy; MV, mechanical ventilation; OR, odds ratio; RR, risk ratio. * Means were estimated based on the median and interquartile ranged reported as by Wan et al. [36].
Table
Table 3. Prevalence of PEW in patients with AKI based on SGA.
Table 3. Prevalence of PEW in patients with AKI based on SGA.
StudySettingnSubjective Global Assessment (%)
Well-NourishedMildly/Moderately MalnourishedSeverely Malnourished
Fiaccadori, 1999 [26]RICU 30942.116.241.7
Berbel, 2014 [21]ICU and wards13339.842.917.3
Guimaraes, 2008 [28]ICU5617.967.814.3
Kritmetapak, 2016 [29]ICU7041.441.417.2
Abbreviations: AKI, acute kidney injury; ICU, intensive care unit; PEW, protein energy wasting; RICU, renal intermediate care unit; SGA, subjective global assessment.

Share and Cite

MDPI and ACS Style

Khor, B.-H.; Tiong, H.-C.; Tan, S.C.; Abdul Rahman, R.; Abdul Gafor, A.H. Protein-Energy Wasting Assessment and Clinical Outcomes in Patients with Acute Kidney Injury: A Systematic Review with Meta-Analysis. Nutrients 2020, 12, 2809. https://doi.org/10.3390/nu12092809

AMA Style

Khor B-H, Tiong H-C, Tan SC, Abdul Rahman R, Abdul Gafor AH. Protein-Energy Wasting Assessment and Clinical Outcomes in Patients with Acute Kidney Injury: A Systematic Review with Meta-Analysis. Nutrients. 2020; 12(9):2809. https://doi.org/10.3390/nu12092809

Chicago/Turabian Style

Khor, Ban-Hock, Hui-Ci Tiong, Shing Cheng Tan, Raha Abdul Rahman, and Abdul Halim Abdul Gafor. 2020. "Protein-Energy Wasting Assessment and Clinical Outcomes in Patients with Acute Kidney Injury: A Systematic Review with Meta-Analysis" Nutrients 12, no. 9: 2809. https://doi.org/10.3390/nu12092809

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop